0001493152-23-020974.txt : 20230714 0001493152-23-020974.hdr.sgml : 20230714 20230612172040 ACCESSION NUMBER: 0001493152-23-020974 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OKYO Pharma Ltd CENTRAL INDEX KEY: 0001849296 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 55 PARK LANE CITY: LONDON STATE: X0 ZIP: W1K 1NA BUSINESS PHONE: 44 (0) 207 495 2379 MAIL ADDRESS: STREET 1: 55 PARK LANE CITY: LONDON STATE: X0 ZIP: W1K 1NA CORRESP 1 filename1.htm

OKYO Pharma Limited

Martello Court

Admiral Park

St. Peter Port

Guernsey GY1 3HB

June 12, 2023

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Daniel Crawford

	Re:	OKYO Pharma Limited
		Registration Statement on Form F-1/A
		June 9, 2023
		File No. 333-272005

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, OKYO Pharma Limited (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Daylight Time, on Wednesday, June 14, 2023, or as soon thereafter as possible.

Please notify Jeff Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

	OKYO Pharma Limited

	By:	/s/ Gary Jacob
	Name:	Gary Jacob
	Title:	Chief Executive Officer

-1-